Genzyme Corporation - Product Pipeline Review - 2016

Published: Feb, 2016 | Pages: 74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Genzyme Corporation - Product Pipeline Review - 2016

Summary


Global Markets Direct's, 'Genzyme Corporation - Product Pipeline Review - 2016', provides an overview of the Genzyme Corporation's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Genzyme Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Genzyme Corporation
- The report provides overview of Genzyme Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Genzyme Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Genzyme Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy


- Evaluate Genzyme Corporation's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Genzyme Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Genzyme Corporation's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Genzyme Corporation Snapshot 6
Genzyme Corporation Overview 6
Key Information 6
Key Facts 6
Genzyme Corporation - Research and Development Overview 7
Key Therapeutic Areas 7
Genzyme Corporation - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Genzyme Corporation - Pipeline Products Glance 14
Genzyme Corporation - Late Stage Pipeline Products 14
Phase III Products/Combination Treatment Modalities 14
Genzyme Corporation - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Genzyme Corporation - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Genzyme Corporation - Drug Profiles 19
patisiran 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
revusiran 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
sargramostim 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
vandetanib 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
GZ-402666 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
olipudase alfa 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ibiglustat 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
GZ-402668 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
VYAADC-01 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
1D-11 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
GENZ-644442 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules for Malaria 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecules to Inhibit PMP22 for Charcot-Marie-Tooth Type 1 A 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Genzyme Corporation - Pipeline Analysis 41
Genzyme Corporation - Pipeline Products by Target 41
Genzyme Corporation - Pipeline Products by Route of Administration 43
Genzyme Corporation - Pipeline Products by Molecule Type 44
Genzyme Corporation - Pipeline Products by Mechanism of Action 45
Genzyme Corporation - Recent Pipeline Updates 46
Genzyme Corporation - Dormant Projects 59
Genzyme Corporation - Discontinued Pipeline Products 61
Discontinued Pipeline Product Profiles 61
GZ-402674 61
GZ-404477 61
tasidotin hydrochloride 61
teriflunomide 61
tolevamer potassium sodium 61
vandetanib 62
Genzyme Corporation - Locations and Subsidiaries 63
Head Office 63
Other Locations & Subsidiaries 63
Genzyme Corporation - Key Manufacturing Facilities 72
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 73
Disclaimer 74

List of Tables

Genzyme Corporation, Key Information 6
Genzyme Corporation, Key Facts 6
Genzyme Corporation - Pipeline by Indication, 2016 8
Genzyme Corporation - Pipeline by Stage of Development, 2016 10
Genzyme Corporation - Monotherapy Products in Pipeline, 2016 11
Genzyme Corporation - Partnered Products in Pipeline, 2016 12
Genzyme Corporation - Partnered Products/ Combination Treatment Modalities, 2016 13
Genzyme Corporation - Phase III, 2016 14
Genzyme Corporation - Phase II, 2016 15
Genzyme Corporation - Phase I, 2016 16
Genzyme Corporation - Preclinical, 2016 17
Genzyme Corporation - Discovery, 2016 18
Genzyme Corporation - Pipeline by Target, 2016 42
Genzyme Corporation - Pipeline by Route of Administration, 2016 43
Genzyme Corporation - Pipeline by Molecule Type, 2016 44
Genzyme Corporation - Pipeline Products by Mechanism of Action, 2016 45
Genzyme Corporation - Recent Pipeline Updates, 2016 46
Genzyme Corporation - Dormant Developmental Projects,2016 59
Genzyme Corporation - Discontinued Pipeline Products, 2016 61
Genzyme Corporation, Other Locations 63
Genzyme Corporation, Subsidiaries 69
Genzyme Corporation, Key Manufacturing Facilities 72